Clinical trials: Anticoagulant
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Healthy
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as…
- Trial name
- NCT04543383
- Testing
- Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Genetic Response to Warfarin in Healthy Subjects
The purpose of this study is to determine the importance of genetic differences on individuals' response to warfarin in a group of healthy subjects.
- Trial name
- NCT01520402
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Ischemic Stroke, Atrial Fibrillation
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
The Purpose of this open-label randomized controlled multicenter trial is to evaluate the efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination therapy with antiplatelet drug, in ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Atherothrombosis
- Trial name
- ATIS-NVAF (NCT03062319)
- Testing
- Oral Anticoagulant, Antiplatelet Drug
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- National Hospital Organization Osaka National Hospital
Atrial Fibrillation
Indonesian Registry on Atrial Fibrillation
Our rationale of creation of this registry stems from the fact that the use of VKA in patients with AF is a double-edged sword, physicians face tremendous burden in assigning patients with VKA, due to risk of Bleeding…
- Trial name
- OneAF (NCT04222868)
- Where
- 25 sites in Indonesia
- Volunteers
- 1,000 people
- Sponsor
- Indonesian Heart Rhythm Society
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Nursing Care, Cold Application
Cold Spray for Pain and Ecchymosis After Anticoagulant Prophylaxis in Orthopedic Surgery
Heparin is a widely used anticoagulant for thrombosis prevention, and low molecular weight heparin (LMWH) has become the preferred option due to its higher bioavailability, strong antithrombotic effect, and lower risk of…
- Conditions
- Nursing Care, Cold Application, Pain, Ecchymosis
- Trial name
- NCT07195955
- Testing
- Cold Spray Application
- Where
- Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Kocaeli University
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Pulmonary Embolism, Venous Thromboembolism
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Atrial Fibrillation
- Trial name
- NCT05351749
- Testing
- New-prescription Alert, New-prescription Alert with referral option, Existing-prescription notification to prescriber
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- University of Michigan
Intracerebral Hemorrhage, Intracerebral Haemorrhage
International Care Bundle Evaluation in Cerebral Hemorrhage Research
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality.
- Conditions
- Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke
- Trial name
- I-CATCHER (NCT06429332)
- Testing
- Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 3,500 people
- Sponsor
- Region Skane
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Patients Undergoing Operative Fixation of Long Bone Fractures Within the Community Medical Centers System
Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma
Tranexamic acid, an anti-fibrinolytic agent, is commonly given after induction of general anesthesia in patients undergoing hip and knee arthroplasty.
- Trial name
- TXA (NCT07116395)
- Testing
- Tranexamic Acid (TXA)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Arbi Nazarian, MD
Heparin-induced Thrombocytopenia
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Heparin-induced thrombocytopenia (HIT) is a rare but potentially serious complication of heparin therapy. , argatroban is the alternative anticoagulant of choice in patients with suspected HIT and renal impairment, high bleeding…
- Trial name
- TIH-FM (NCT06066762)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation
Adherence to New Oral Anticoagulation Therapy in Turkey
This study will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkish Population.
- Trial name
- NOAC-TR (NCT02480920)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,738 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Aortic Valve Stenosis
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
This trial is to compare the efficacy of NOAC(Novel Oral Anticoagulants) with edoxaban vs. dual antiplatelet therapy (DAPT) for prevention of leaflet thrombosis (documented by cardiac CT imaging) and cerebral embolization…
- Trial name
- ADAPT-TAVR (NCT03284827)
- Testing
- NOAC, DAPT
- Where
- 5 sites in Hong Kong, South Korea and 1 more
- Volunteers
- 235 people
- Sponsor
- Duk-Woo Park, MD
Covid19
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential…
- Trial name
- ASPEN (NCT04655586)
- Testing
- rNAPc2, Heparin
- Where
- 24 sites in United States, Argentina and 1 more
- Volunteers
- 160 people
- Sponsor
- ARCA Biopharma, Inc.
Post Operative Hemorrhage
Direct Oral Anticoagulants and Management of Blleding Following Dental Extractions. A Prospective Cohort Study.
Evaluation of DOACs treatment on post-extraction bleeding
- Trial name
- DOACS_1 (NCT06365242)
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- University of Pisa
Atrial Fibrillation, Venous Thromboembolism
The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)
Anticoagulants are used to prevent thrombotic events in patients with predisposing factors. However, the use of such therapies is associated with bleeding complications, which can be a serious safety issue.
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- START-Portugal (NCT03977363)
- Testing
- Anticoagulant drugs
- Where
- Portugal
- Volunteers
- 25 people
- Sponsor
- CHAD
Prostheses and Implants, Stroke
Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
Mechanical heart valves (MHV) demand lifelong anticoagulation with vitamin K antagonists (VKA) due to the high thrombogenicity of the prosthesis.
- Conditions
- Prostheses and Implants, Stroke, Valve Heart Disease, Anticoagulants and Bleeding Disorders
- Trial name
- RIWA (NCT03566303)
- Testing
- Rivaroxaban 15 mg, Warfarin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Geral Roberto Santos
Cardiovascular Diseases
Anticoagulation, Vitamins, and Endothelial Function
Determine whether low or high dose B vitamin therapy will lower homocysteine and thrombomodulin in patients anticoagulated with warfarin.
- Trial name
- NCT00018460
- Testing
- Vitamin B
- Where
- United States
- Sponsor
- US Department of Veterans Affairs